pharmaphorum1d
Jardiance cleared in EU for CKD, challenging Forxiga
Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...
pharmaphorum8d
FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney disease
The FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new use, to reduce the risk of renal failure and cardiovascular death in people with chronic ...
MedPage Today on MSN15d
Updated CKD Guidelines Promote Cystatin C, Risk Equations, and SGLT2 Inhibitors
Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's updated clinical practice guideline. In a synopsis of the recently ...